On Friday the Pressure BioSciences Inc (OTCMKTS:PBIO) stock was trading within a range but in this context it is important to note that the company had actually made a key announcement the day before.
On Friday, PBIO stock ended flat at $2.50 with more than 8.22K shares, compared to its average volume of 26.84K shares. The stock has moved within a range of $2.3600 – 2.5000 after opening the trade at $2.50.
The company is a leader in the development and sales of high pressure based instruments that can be deployed across many industries. On November 4 the company announced that it was going to strategically expand its proprietary BaroFold technology platform. The company plans to expand through the growth of sales, services and leasing. It was a major announcement from Pressure BioSciences and it remains to be seen if investors react to the news this week or not.
The expansion of the BaroFold technology platform could be a timely move from Pressure BioSciences considering the fact that proteins have become a vital component when it comes to the development of therapeutic medicines. Studies suggest that the global protein therapeutics space could hit a valuation of as much as $233 billion by 2027. Hence, the move is an important one and it should be noted that manufacturing proteins is a highly specialised process, which is why the demand for effective platforms is also there.
Dr. Alexander V. Lazarev, PBI’s Chief Science Officer, said: “The biosimilars market for generic biotherapeutics is rapidly expanding worldwide and it demands lower costs of biotherapeutics. Biomanufacturing throughput and production costs can be slashed significantly if protein drugs are expressed in bacterial cells. Traditionally, bacterial systems were considered inferior to the cell cultures obtained from higher organisms due to higher incidence of certain issues, such as the formation of aggregates and the “misfolding” of polypeptides that fold in a specific pattern to give a protein its function. PBI’s BaroFold™ technology platform, based on the innovative use of high pressure and protected by the Company’s eight issued patent families, offers a uniquely gentle, exquisitely controllable, and cost-effective way to address these manufacturing challenges. To capitalize on this opportunity, PBI launched the BaroFold Biopharma Services Business (“BaroFold Services”) in 2019.”
PBIO stock is trading above the 20-Day and 50-Day Moving averages of $2.43 and $2.49 respectively. Moreover, the stock is trading above the 200-Day moving average of $2.40. The stock is up 76% so far this year.